Liên Minh Châu Âu - Tiếng Latvia - EMA (European Medicines Agency)

novartis europharm limited - deferasirox - beta-thalassemia; iron overload - visi pārējie terapeitiskie produkti - exjade norāda attieksmi pret hronisku dzelzs pārslodzes dēļ bieža asins pārliešanas (≥ 7 ml/kg/mēnesī iepakoto sarkano asinsķermenīšu) pacientiem ar beta thalassaemia major sešu gadu vecu un vecāku. exjade ir arī indicēts, lai ārstētu hronisku dzelzs pārslodzes dēļ, asins pārliešanas, kad deferoksamīna terapija ir kontrindicēta vai piemēroti šādām pacientu grupām:pacientiem ar beta thalassaemia ar lielu dzelzs pārslodzi, jo bieži asins pārliešanas (≥ 7 ml/kg/mēnesī, kas pildīta sarkano asins šūnu) vecumā no diviem līdz pieciem gadiem;pacientiem ar beta thalassaemia ar lielu dzelzs pārslodzi, jo reti asins pārliešanas (< 7 ml/kg/mēnesī, kas pildīta sarkano asins šūnu) vecumā līdz diviem gadiem un vecāki;pacientiem ar citām anēmijas vecumā no diviem gadiem un vecāki. exjade ir arī indicēts, lai ārstētu hronisku dzelzs pārslodzi, kas prasa helātu terapija, ja deferoksamīna terapija ir kontrindicēta vai nepietiekama pacientiem ar ne-asins pārliešanas atkarīgas no thalassaemia sindromi, vecumā no 10 gadiem un vecāki.

Latvia - Tiếng Latvia - Zāļu valsts aģentūra

umedica netherlands b.v., netherlands - deferazirokss - apvalkotā tablete - 90 mg

Latvia - Tiếng Latvia - Zāļu valsts aģentūra

umedica netherlands b.v., netherlands - deferazirokss - apvalkotā tablete - 180 mg

Latvia - Tiếng Latvia - Zāļu valsts aģentūra

umedica netherlands b.v., netherlands - deferazirokss - apvalkotā tablete - 360 mg

Liên Minh Châu Âu - Tiếng Latvia - EMA (European Medicines Agency)

amgen europe b.v. - adalimumab - arthritis, psoriatic; colitis, ulcerative; arthritis, juvenile rheumatoid; spondylitis, ankylosing; psoriasis; crohn disease; arthritis, rheumatoid - imūnsupresanti - rheumatoid arthritis  amgevita in combination with methotrexate, is indicated for: , the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. , ārstēšana smagas, aktīva un progresējoša reimatoīdais artrīts pieaugušajiem, kas nav iepriekš apstrādātas ar metotreksātu. ,  amgevita can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. amgevita samazina likmes progresiju locītavu bojājumu, ko mēra ar x-ray un uzlabo fizisko funkciju, ja to lieto kopā ar metotreksātu. juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis amgevita in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). amgevita var tikt dota monotherapy gadījumā, ja nepanes metotreksātu vai, ja turpina terapiju ar metotreksātu ir nepiemērots (par iedarbīgumu monotherapy skatīt nodaĝā 5. adalimumab nav pētīta pacientiem, kas jaunāki par 2 gadiem,. enthesitis-related arthritis amgevita is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5. axial spondyloarthritis ankylosing spondylitis (as) amgevita is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. axial spondyloarthritis without radiographic evidence of as amgevita is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and/or mri, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs. psoriatic arthritis amgevita is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. amgevita samazina ātrumu progresēšanu, perifēro locītavu bojājumu, ko mēra ar x-ray pacientiem ar poliartikulāru simetriski apakštipu slimības (skatīt 5. iedaļu. 1) un uzlabo fizisko funkciju. psoriasis amgevita is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasis amgevita is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs) amgevita is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy (see sections 5. 1 un 5. crohn’s disease amgevita is indicated for treatment of moderately to severely active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's disease amgevita is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies. ulcerative colitis amgevita is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitis amgevita is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitis amgevita is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

Liên Minh Châu Âu - Tiếng Latvia - EMA (European Medicines Agency)

laboratorios lesvi s.l. - dimethyl fumarate - multiplā skleroze, recidivējoši-pārskaitot - imūnsupresanti - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Liên Minh Châu Âu - Tiếng Latvia - EMA (European Medicines Agency)

sanofi b.v. - sevelamēra karbonāts - hyperphosphatemia; renal dialysis - visi pārējie terapeitiskie produkti - renvela ir indicēts hiperfosfatēmijas kontrolei pieaugušiem pacientiem, kas saņem hemodialīzi vai peritoneālo dialīzi. renvela ir arī norādīts par kontroli hyperphosphataemia pieaugušiem pacientiem ar hronisku nieru slimību nav dialīzi ar seruma fosfora ≥ 1. 78 mmol/l. renvela būtu jāizmanto saistībā ar vairākiem terapijas metodi, kas varētu ietvert kalcija papildināt, 1,25-dihidroksi vitamīns d3 vai vienā no tās analogiem, lai kontrolētu attīstību, nieru mazspēja, kaulu slimība.

Liên Minh Châu Âu - Tiếng Latvia - EMA (European Medicines Agency)

sanofi b.v. - sevelamēra karbonāts - hyperphosphatemia; renal dialysis - visi pārējie terapeitiskie produkti - sevelamer karbonāts winthrop ir norādīts kontroles hyperphosphataemia pieaugušo pacientiem, kas saņem hemodialīzes vai peritoneālās dialīzes. sevelamer karbonāts winthrop ir arī norādīts par kontroli hyperphosphataemia pieaugušiem pacientiem ar hronisku nieru slimību nav dialīzi ar seruma fosfora > 1. 78 mmol/l. sevelamer karbonāts winthrop būtu jāizmanto saistībā ar vairākiem terapijas metodi, kas varētu ietvert kalcija papildināt, 1,25-dihidroksi vitamīns d3 vai vienā no tās analogiem, lai kontrolētu attīstību, nieru mazspēja, kaulu slimība.

Latvia - Tiếng Latvia - Zāļu valsts aģentūra

pfizer europe ma eeig, belgium - medroksiprogesterona acetāts - suspensija injekcijām pilnšļircē - 150 mg/1 ml

Latvia - Tiếng Latvia - Zāļu valsts aģentūra

pfizer europe ma eeig, belgium - medroksiprogesterona acetāts - suspensija injekcijām - 150 mg/1 ml